vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Biomea Fusion, Inc. (BMEA). Click either name above to swap in a different company.
Biomea Fusion, Inc. runs the higher net margin — -130.8% vs -95337.1%, a 95206.3% gap on every dollar of revenue.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Biomea Fusion, Inc.BMEAEarnings & Financial Report
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel covalent small molecule therapies for genetically defined cancers and other serious life-threatening diseases. Its lead pipeline candidates target key oncogenic drivers, addressing high unmet medical needs across global patient populations.
ASBP vs BMEA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $-3.5M |
| Net Profit | $-1.9M | $4.6M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | 332.4% |
| Net Margin | -95337.1% | -130.8% |
| Revenue YoY | — | -556.7% |
| Net Profit YoY | -755.6% | 115.7% |
| EPS (diluted) | $-0.04 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $-3.5M | ||
| Q3 25 | $1.9K | — | ||
| Q3 22 | — | $165.0M | ||
| Q2 22 | — | $0 | ||
| Q1 22 | — | $1.1B |
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-1.9M | — | ||
| Q3 22 | — | $-22.9M | ||
| Q2 22 | — | $-17.3M | ||
| Q1 22 | — | $-16.4M |
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q4 25 | — | 332.4% | ||
| Q3 25 | -59015.8% | — | ||
| Q3 22 | — | -14.2% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | -1.5% |
| Q4 25 | — | -130.8% | ||
| Q3 25 | -95337.1% | — | ||
| Q3 22 | — | -13.9% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | -1.5% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | $-0.04 | — | ||
| Q3 22 | — | $-0.78 | ||
| Q2 22 | — | $-0.59 | ||
| Q1 22 | — | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $29.6M |
| Total Assets | $2.4M | $58.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $55.8M | ||
| Q3 25 | — | — | ||
| Q3 22 | — | $133.5M | ||
| Q2 22 | — | $149.6M | ||
| Q1 22 | — | $164.8M |
| Q4 25 | — | $29.6M | ||
| Q3 25 | $-11.5M | — | ||
| Q3 22 | — | $130.6M | ||
| Q2 22 | — | $150.4M | ||
| Q1 22 | — | $164.8M |
| Q4 25 | — | $58.6M | ||
| Q3 25 | $2.4M | — | ||
| Q3 22 | — | $145.1M | ||
| Q2 22 | — | $161.7M | ||
| Q1 22 | — | $174.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-13.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -3.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-13.9M | ||
| Q3 25 | $-1.1M | — | ||
| Q3 22 | — | $-16.8M | ||
| Q2 22 | — | $-15.4M | ||
| Q1 22 | — | $-10.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q3 22 | — | $-16.8M | ||
| Q2 22 | — | $-15.7M | ||
| Q1 22 | — | $-10.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q3 22 | — | -10.2% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | -0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q3 22 | — | 0.0% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | 0.0% |
| Q4 25 | — | -3.02× | ||
| Q3 25 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
